Current Clinical Trials

A Phase 1/2 Study of the Highly selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Study identifier: BLU-667-1101
Sponsor: Blueprint Medicines Corporation
Open to enrollment
Principal investigator:
   

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases
Study identifier: P4M060
Sponsor: Precision for Medicine
Open to enrollment
Principal investigator: Abhinav Chandra, M.D.

Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Study identifiers: MT1410-A, MT0271, MT2221
Sponsor: MT Group
Open to enrollment
Principal investigator: Makardhwaj Shrivastava, M.D.

The LuCED® Test for Early Lung Cancer Detection: Sample Collection for Test Development
Study identifier: VG #100-02867
Sponsor: VisionGate
Open to enrollment
Principal investigator: Abhinav Chandra, M.D.

 

If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at [email protected].

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma
Study identifier: ZW25-201
Sponsor: Zymeworks Inc.
Open to enrollment
Principal investigator:
   

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients
Study identifier: 18-214-10
Sponsor: Nektar Therapeutics
Open to enrollment
Principal investigator:
   

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

A Phase 1/2 Study of the Highly selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Study identifier: BLU-667-1101
Sponsor: Blueprint Medicines Corporation
Open to enrollment
Principal investigator:
 

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Study identifier: 2102-hem-101
Sponsor: Forma Therapeutics, Inc
Open to enrollment
Principal investigator:

A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Study identifier: Onconova 04-30
Sponsor: Onconova Therapeutics, Inc.
Open to enrollment
Principal investigator:  

If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at [email protected].

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Study identifier: MRTX-500
Sponsor: Mirati Therapeutics
Open to enrollment
Principal investigator: Abhinav Chandra, M.D.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Study identifier: 516-005
Sponsor: Mirati Therapeutics
Open to enrollment
Principal investigator: Raju Vaddepally, M.D.

A Phase 1/2 Study of the Highly selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Study identifier: BLU-667-1101
Sponsor: Blueprint Medicines Corporation
Open to enrollment
Principal investigator:

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer
Study identifier: ARRAY-818-202
Sponsor: Array BioPharma
Open to enrollment
Principal investigator:

A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients with Non-Small Cell Lung Cancer that Harbors either EGFR Exon 20 Insertion or a HER2-Activating Mutation
Study identifier: Rain-701
Sponsor: Rain Therapeutics Inc.
Open to enrollment
Principal investigator:

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Study identifier: Tak 788-3001
Sponsor: Millennium Pharmaceuticals, Inc.
Open to enrollment
Principal investigator:
 

If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at [email protected].

A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus Standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s
Study identifier: Chronos 4
Sponsor: Bayer
Open to enrollment
Principal investigator:

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL
Study identifier: MT-002
Sponsor: Molecular Templates, Inc.
Open to enrollment
Principal investigator:

PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Study identifier: MT-003
Sponsor: Molecular Templates, Inc.
Open to enrollment
Principal investigator:
 

If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at [email protected].

The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Study identifier: OMS-I103 PISCES
Sponsor: OncoSec Medical Incorporated
Open to enrollment
Principal investigator:
 

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

Assessment of Primary Prevention Patients Receiving An ICD – Systematic Evaluation of ATP
Study Identifier: APPRAISE ATP C1924
Sponsor: Boston Scientific Corporation
Open to enrollment
Principal Investigator: David Meyer, MD
 

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].

The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared tothe Medtronic IN.PACT® Admiral® Drug-Coated Balloon
Study Identifier: TRANSCEND SUR17-011
Sponsor: Surmodics
Follow up enrollment status
Principal Investigator: Joseph Cardenas, MD

ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon ILLUMENATE Pivotal Post-Approval Study
Study Identifier: TP-1397 Illumenate Pivotal
Sponsor: Spectranetics Corporation
Principal Investigator: Joseph Cardenas, MD

Tack Optimized Balloon Angioplasty Study for the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System (TOBA II)
Tack Optimized Balloon Angioplasty Study for the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System (TOBA II)
Study Identifier: TOBA II CA 0119
Sponsor: IntactVascular
Follow up enrollment status
Principal Investigator: Joseph Cardenas, MD

A randomIzed trial coMParing the ELUVIA™ dRug-elutIng stent versus Zilver® PTX® stent for treatment of superficiAL femoral and/or proximal popliteal arteries (IMPERIAL)
A randomIzed trial coMParing the ELUVIA™ dRug-elutIng stent versus Zilver® PTX® stent for treatment of superficiAL femoral and/or proximal popliteal arteries (IMPERIAL)
Study Identifier: Imperial S2063
Sponsor: Boston Scientific Corporation
Follow up enrollment status
Principal Investigator: Joseph Cardenas, MD

Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System® (TOBA II - BTK)
Study Identifier: TOBA II BTK CA 0137
Sponsor: IntactVascular
Follow up enrollment status
Principal Investigator: Joseph Cardenas, MD

A prospective, global, multi-center study with a randomized controlled trial (RCT) component and a Vessel Preparation Registry (VP) component
Study Identifier: Spectranetics BTK D032150
Sponsor: Spectranetics
Follow up enrollment status
Principal Investigator: Joseph Cardenas, MD
 

If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at [email protected].

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection (PROFILE)
Study Identifier: LBS-POI-201
Sponsor: Leading BioSciences
Open to enrollment
Principal Investigator: Bharat Magu, MD
 

If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at [email protected].